Author:
McGranahan Tresa,Nagpal Seema
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference107 articles.
1. •• Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA). JAMA Oncol. 2016; doi:
10.1001/jamaoncol.2016.3834
. Updated prognositc scale for BrM in lung cancer accounting for mutational status.
2. • Sholl LM. Biomarkers in lung adenocarcinoma: a decade of progress. Arch Pathol Lab Med. 2015;139(4):469–80. doi:
10.5858/arpa.2014-0128-RA
. Review of mutations in lung adenocardinoma.
3. Swanton C, Govindan R. Clinical implications of genomic discoveries in lung cancer. N Engl J Med. 2016;374(19):1864–73. doi:
10.1056/NEJMra1504688
.
4. Hendler FJ, Ozanne BW. Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest. 1984;74(2):647–51. doi:
10.1172/jci111463
.
5. Di Carlo A, Mariano A, Coppa A, Macchia V, Maiuri F, Iaconetta G, et al. Epidermal growth factor receptor and tissue tumor markers in human intracranial neoplasms. J Neurosurg Sci. 1990;34(3–4):181–5.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献